Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CVS$80.83+0.84(+1.05%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETGOOG$290.00+2.70(+0.94%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.96-1.32(-2.26%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,459.08-37.06(-2.48%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.78+0.92(+0.90%)Transaction in Own Shares8:00:53 AM ETIBM$256.00+1.68(+0.66%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$631.85+1.85(+0.29%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.00+1.81(+0.38%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$290.00+2.70(+0.94%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.71+5.20(+1.49%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.00+1.68(+0.66%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$197.01-3.28(-1.64%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.71+5.20(+1.49%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.90+0.68(+0.24%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.23-4.47(-2.60%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.13+1.33(+0.24%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$153.40-19.79(-11.43%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.01+1.13(+1.18%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ET

LXRX · NASDAQ

Lexicon Pharmaceuticals, Inc.

$1.52 +0.04 (+2.70%)

Company overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products. Its orally delivered small molecule drug candidates under development include Sotagliflozin, which completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$676M
Employees
103
Headquarters
The Woodlands, TX
Website
lexpharma.com
CEO
Michael S. Exton
Listed
April 7, 2000
P/E
-21.71
Dividend yield
0.00%

Company financials

Revenue
$69.6M
Gross profit
$69M
Operating income
-$24.2M
EBITDA
-$20.4M
Net income
-$26.1M
EPS
-$0.07
Total assets
$269M
Total debt
$57.7M
Gross margin
99.07%
Net margin
-37.46%
Earnings yield
-4.61%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

1.311.672.022.382.73
LXRX 1D NASDAQ O1.50H1.54L1.46C1.49+0.03 (+1.71%)Vol1.36M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharma Q3 revenue declines on lower milestone payments Reuters
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Stock news BRIEF-Lexicon Pharmaceuticals Q3 EPS USD -0.03 Reuters
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More Seeking Alpha
LXRXLexicon Pharmaceuticals, Inc. Stock news Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today The Motley Fool
LXRXLexicon Pharmaceuticals, Inc. Stock news This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Benzinga
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data Defense World
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data MarketBeat
LXRXLexicon Pharmaceuticals, Inc. Stock news Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Benzinga
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Press release Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 GlobeNewswire
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets Seeking Alpha
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals Q2 Earnings Call Highlights MarketBeat
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript Seeking Alpha
LXRXLexicon Pharmaceuticals, Inc. Stock news Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates Zacks Investment Research
See more
FAQ

Questions about Lexicon Pharmaceuticals, Inc.

What does Lexicon Pharmaceuticals, Inc. do?
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products. Its orally delivered small molecule drug candidates under development include Sotagliflozin, which completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
What is LXRX's market cap?
Lexicon Pharmaceuticals, Inc. (LXRX) is a listed stock with a live quote. The latest market cap on this page is $676M.
Where is Lexicon Pharmaceuticals, Inc. headquartered?
Lexicon Pharmaceuticals, Inc. is headquartered in The Woodlands, TX.
How do I get LXRX news from the API?
Call GET /v1/news?tickers=LXRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does LXRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for LXRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the LXRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs